Dive into the archives.
- Hot off the AAN Press: Tysabri May Reverse MS Damage
UPDATE 1-Elan’s Tysabri may reverse MS damage, shares up April 29 (Reuters) – Elan’s Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec said on Wednesday, boosting Elan’s shares 10 percent. Data released by the companies at the American Academy of Neurology showed [...]
- Biogen Idec announces sixth case of PML linked to use of Tysabri
Biogen Idec reported that another patient with multiple sclerosis taking Tysabri (natalizumab) was diagnosed with progressive multifocal leukoencephalopathy (PML) earlier this month, raising the total number of cases to six since July 2006. Biogen Idec’s shares were down as much as 4.3 percent. The patient had been taking Tysabri for 31 months before developing the [...]
- Biogen Receives FDA Warning for Tysabri (re Internet Ads)
FDA Warns Drug Firms Over Internet Ads WASHINGTON — The Food and Drug Administration warned 14 major pharmaceutical companies about brief Internet ads that accompany searches on Google and other search engines, saying the ads were misleading because they didn’t include risk information. The warnings marked one of the first major actions by the FDA [...]
- Biogen hopes to have PML-related test by year-end
By Toni Clarke BOSTON (Reuters) – Biogen Idec Inc said on Wednesday it is developing a test that can identify the presence of a virus that can cause a potentially deadly brain infection in certain patients taking its multiple sclerosis drug Tysabri, and hopes to have it available by year-end. Cecil Pickett, Biogen’s head of [...]
- Malaria Pill=The End of PML?
Elan shares soar on news of possible Tysabri side-effect treatment SHARES IN drug company Elan bounced more than 10 per cent yesterday after news emerged of a possible treatment for a potentially fatal side effect of its multiple sclerosis therapy, Tysabri. Biogen Idec, Elan’s partner in the development and sale of Tysabri, is testing the [...]
